# reload+after+2024-01-23 12:44:32.421619
address1§451 D Street
address2§5th Floor Suite 501
city§Boston
state§MA
zip§02210
country§United States
phone§857-209-0050
website§https://elicio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
fullTimeEmployees§23
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert T. Connelly', 'age': 63, 'title': 'CEO, President & Director', 'yearBorn': 1960, 'fiscalYear': 2020, 'totalPay': 612000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher M. Haqq M.D., Ph.D.', 'age': 57, 'title': 'Executive VP, Head of Research & Development and Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2020, 'totalPay': 589000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Darrell J. Irvine Ph.D.', 'title': 'Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board', 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian  Piekos', 'age': 48, 'title': 'Chief Financial Officer', 'yearBorn': 1975, 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  DiVecchia', 'title': 'Senior Vice President of Operations & Human Resources', 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Peter  DeMuth Ph.D.', 'age': 37, 'title': 'Chief Scientific Officer', 'yearBorn': 1986, 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Esther  Welkowsky', 'title': 'Senior Vice President of Clinical Development', 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Joy  Seymour', 'title': 'VP & Head of Regulatory Affairs', 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'John J. Concannon III', 'title': 'Secretary', 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§10
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1609372800
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-3.03
exchange§NGM
quoteType§EQUITY
shortName§Elicio Therapeutics, Inc.
longName§Elicio Therapeutics, Inc.
firstTradeDateEpochUtc§1612535400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f5a7063e-a200-3645-afdf-a5955dd38a4c
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§12.0
targetMeanPrice§12.0
targetMedianPrice§12.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§1.229
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
